FY2029 Earnings Forecast for APRE Issued By Wedbush

Aprea Therapeutics, Inc. (NASDAQ:APRE) – Equities research analysts at Wedbush issued their FY2029 EPS estimates for Aprea Therapeutics in a research note issued to investors on Tuesday, March 25th. Wedbush analyst R. Driscoll forecasts that the company will post earnings of $2.19 per share for the year. Wedbush has a “Outperform” rating and a $11.00 price target on the stock. The consensus estimate for Aprea Therapeutics’ current full-year earnings is ($2.55) per share.

Aprea Therapeutics (NASDAQ:APRE) last announced its earnings results on Tuesday, March 25th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.20. The firm had revenue of $0.21 million during the quarter, compared to analysts’ expectations of $0.15 million. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Aprea Therapeutics in a research report on Wednesday, January 15th.

Aprea Therapeutics Stock Performance

Shares of APRE stock opened at $2.09 on Thursday. Aprea Therapeutics has a 1 year low of $2.09 and a 1 year high of $6.70. The stock has a market cap of $11.36 million, a PE ratio of -0.74 and a beta of 0.82. The stock has a fifty day moving average price of $3.03 and a 200 day moving average price of $3.23.

Hedge Funds Weigh In On Aprea Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets acquired a new stake in shares of Aprea Therapeutics during the 4th quarter valued at $43,000. LPL Financial LLC bought a new stake in shares of Aprea Therapeutics during the 4th quarter valued at $53,000. Landscape Capital Management L.L.C. bought a new stake in shares of Aprea Therapeutics in the fourth quarter worth about $116,000. Finally, Stonepine Capital Management LLC boosted its position in Aprea Therapeutics by 8.8% during the 4th quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company’s stock worth $491,000 after acquiring an additional 12,047 shares during the last quarter. Institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.